Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2197808 | 0.90 | HTT (0.48) | PDE10AKMT2AMEN1HTTRAB9A | |
| SCHEMBL2197118 | 0.89 | HTR2A (0.53) | PDE10AKMT2AMEN1HTTRAB9A | |
| SCHEMBL2197355 | 0.84 | KMT2A (0.46) | PDE10AKMT2AMEN1HTTRAB9A | |
| SCHEMBL2195845 | 0.82 | HTR2A (0.56) | PDE10AKMT2AMEN1HTTRAB9A | |
| SCHEMBL3909234 | 0.81 | GRM5 (0.51) | KMT2AMEN1HTTMAPK1HTR1A | |
| SCHEMBL2195199 | 0.81 | MEN1 (0.46) | KMT2AMEN1HTTNPSR1MAPK1 | |
| SCHEMBL2198492 | 0.79 | HSP90AA1 (0.57) | PDE10AKMT2AMEN1LMNAHSP90AA1 | |
| SCHEMBL2196081 | 0.79 | KMT2A (0.49) | PDE10AKMT2AMEN1HTR2ANPY1R | |
| SCHEMBL2195107 | 0.77 | MEN1 (0.56) | PDE10AKMT2AMEN1HTTRAB9A | |
| SCHEMBL4232976 | 0.74 | HTR2A (0.47) | KMT2AMEN1HSP90AA1HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236947-B2 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LIMITED (GB) | 2012-08-07 | — | — | US | disclosed |
| EP-1956004-B1 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LTD (GB) | 2012-06-13 | — | — | EP | disclosed |
| US-20110237792-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED | 2011-09-29 | — | — | US | disclosed |
| US-7977337-B2 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LIMITED (GB) | 2011-07-12 | — | — | US | disclosed |
| US-20100305107-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED | 2010-12-02 | — | — | US | disclosed |
| US-7799774-B2 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-20090298841-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090036682-A1 | Quinoline Derivatives and Their Use as 5-HT6 Ligands | GLAXO GROUP LIMITED | 2009-02-05 | — | — | US | disclosed |
| EP-1956004-A1 | Quinoline derivatives and their use as 5-HT6 ligands | Glaxo Group Limited (GB) | 2008-08-13 | — | — | EP | disclosed |
| US-20050124628-A1 | Novel compounds | ROIVANT NEUROSCIENCES LTD. (BM) | 2005-06-09 | — | — | US | disclosed |
| EP-1497266-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003080580-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298841-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR3B, HTR4 | PDE10A 1057/4885KMT2A 2088/4885MEN1 1466/4885 |
| US-20050124628-A1 | Novel compounds | NLN, ATP6V1B2, CHRNA2 | PDE10A 497/4885KMT2A 2441/4885MEN1 2236/4885 |
| US-20110237792-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR1A, HTR7 | PDE10A 1208/4885KMT2A 1762/4885MEN1 817/4885 |
| US-20100305107-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR1A, HTR7 | PDE10A 1208/4885KMT2A 1762/4885MEN1 817/4885 |
| US-20090036682-A1 | Quinoline Derivatives and Their Use as 5-HT6 Ligands | HTR6, HTR3B, HTR4 | PDE10A 1057/4885KMT2A 2088/4885MEN1 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.